Furthermore, Recursion announced plans for a public offering of $200 million worth of Class A common stock, led by Goldman Sachs & Co. LLC and J.P. Morgan. Lastly, the company has seen significant ...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...

Recursion Pharmaceuticals saw its stock price increase by 12% over the past week. This movement could be associated with several recent developments. The company announced a significant follow-on ...

KeyBanc Capital Markets maintained its Overweight rating for Recursion following the FDA approval. In addition, Recursion announced a $30 million deal with Genentech and plans for a $200 million ...

On Tuesday, KeyBanc reaffirmed its Overweight rating and $12.00 price target for Recursion Pharmaceuticals (NASDAQ:RXRX), following the announcement of Phase 2 trial results for REC-994. The ...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (RXRX) (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...

The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share. This is an increase of 7.12% from the prior estimate of 16.03 dated August 31, ...

NEW HAVEN, Conn., September 03, 2025--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for ...

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...